Volume : 08, Issue : 12, December – 2021

Title:

13.DETERMINATION OF THE DYSPLASIA SYNDROME EXPLORATION PERCENTAGE AND ITS RECOGNITION OCCURRENCE IN INHABITANTS

Authors :

Dr Mudasir Ahmad Dar, Dr Rida Lateef, Dr Tehreem Fatima Lashari

Abstract :

The lack of information about this disease is confirmed by examining the two studies. In these studies, 44 patients present in interior clinics and outpatients observing interior cases were included. The identification of the Myelodysplastic syndrome (MDS) was carried out on an old patient. The age of the patient was about 70 years. He contains 9.2 g/Dl hemoglobin in blood. No recommendation was given to the patient from PCP in spite of the bad condition of the patient. He was already suffering from cardiovascular disorder and lungs dysfunction. Another observation on the same disorder was made on the male of 75 ages. He was continuously expressing the indications of the disorder from the last half a year. He has 7.3 hemoglobin amounts in blood and was suffering from exhaustion. He needs more concentration and improves for further treatment. In this report we are trying to designate the causes because of which we cannot treat the patients of MDS. These cases observed earlier were added in the study to learn the indication of the disorder. We will try to better the identification, initial recommendation and cure of the disease. Myelodysplastic disease is not well identified by the doctors.
Place and duration: In the community medicine department of Sir Ganga Ram Hospital Lahore for Six months duration from December 2017 to May 2018.
Keywords: Anemia; Diagnosis; Elderly patients; Myelodysplastic syndrome; Primary physician; under diagnosis

Cite This Article:

Please cite this article in press Mudasir Ahmad Dar et al, Determination Of The Dysplasia Syndrome Exploration Percentage And Its Recognition Occurrence In Inhabitants., Indo Am. J. P. Sci, 2021; 08(12).

Number of Downloads : 10

References:

1. Gondek, Lukasz P., and Amy E. DeZern. “Assessing clonal haematopoiesis: clinical burdens and benefits of diagnosing myelodysplastic syndrome precursor states.” The Lancet Haematology (2019).
2. Locatelli, Franco, and Brigitte Strahm. “How I treat myelodysplastic syndromes of childhood.” Blood, The Journal of the American Society of Hematology 131, no. 13 (2018): 1406-1414.
3. Stones, D. K. “Fanconi anaemia: A perspective on phenotype, investigations and outcomes from central South Africa.” South African Journal of Child Health 13, no. 4 (2019): 179-185.
4. Kuendgen, Andrea, Catharina Müller-Thomas, Michael Lauseker, Torsten Haferlach, Petra Urbaniak, Thomas Schroeder, Carolin Brings et al. “Efficacy of azacitidine is independent of molecular and clinical characteristics-an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literature.” Oncotarget 9, no. 45 (2018): 27882.
5. Terakura, Seitaro, Tetsuya Nishida, Masashi Sawa, Tomonori Kato, Kotaro Miyao, Yukiyasu Ozawa, Tatsunori Goto et al. “Prospective evaluation of alternative donor from unrelated donor and cord blood in adult acute leukemia and myelodysplastic syndrome.” Bone Marrow Transplantation (2020): 1-11.
6. Reinwald, Mark, Jose T. Silva, Nicolas J. Mueller, Jesús Fortún, Christian Garzoni, Johan W. de Fijter, Mario Fernández-Ruiz, Paolo Grossi, and Jose María Aguado. “ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors).” Clinical Microbiology and Infection 24 (2018): S53-S70.
7. Davidsson, Josef, Andreas Puschmann, Ulf Tedgård, David Bryder, Lars Nilsson, and Jörg Cammenga. “SAMD9 and SAMD9L in inherited predisposition to ataxia, pancytopenia, and myeloid malignancies.” Leukemia 32, no. 5 (2018): 1106-1115.
8. Forghieri, Fabio, Patrizia Comoli, Roberto Marasca, Leonardo Potenza, and Mario Luppi. “Minimal/measurable residual disease monitoring in NPM1-mutated acute myeloid leukemia: a clinical viewpoint and perspectives.” International journal of molecular sciences 19, no. 11 (2018): 3492.
9. Santini, Valeria. “Society of Hematologic Oncology (SOHO) State of the Art Updates and Next Questions: Myelodysplastic Syndromes.” Clinical Lymphoma Myeloma and Leukemia 18, no. 8 (2018): 495-500.
10. Stomper, Julia, Gabriele Ihorst, Stefan Suciu, Philipp N. Sander, Heiko Becker, Pierre W. Wijermans, Christoph Plass et al. “Fetal hemoglobin induction during decitabine treatment of elderly patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: a potential dynamic biomarker of outcome.” haematologica 104, no. 1 (2019): 59-69.
11. Ramaswami, Ramya, Ronald Bayer, and Sandro Galea. “Precision medicine from a public health perspective.” Annual review of public health 39 (2018): 153-168.
12. Deshpande, Shubhangi V., Varsha Y. Godbole, and Archana D. Asher. “Pancytopenia: the perspective from Western Gujarat, India.” International Journal of Advances in Medicine 6, no. 3 (2019): 731.
13. Flotho, Christian, Sebastian Sommer, and Michael Lübbert. “DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemia.” In Seminars in cancer biology, vol. 51, pp. 68-79. Academic Press, 2018.
14. Bradley, G., and M. A. Magalhaes. “Oral manifestation of systemic diseases—a perspective from an oral pathology diagnostic service.” Oral diseases 24, no. 1-2 (2018): 219-223.
15. Sallman, David A., and Alan List. “The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes.” Blood, The Journal of the American Society of Hematology 133, no. 10 (2019): 1039-1048.